ArticleEuropean journal of human genetics : EJHG2010
Frequent genetic differences between matched primary and metastatic breast cancer provide an approach to identification of biomarkers for disease progression.
Article in European journal of human genetics : EJHG, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 45 citations in OpenAlex.
- PHAROS: turning single-cell perturbation models into target-directed drug-combination screens.bioRxiv : the preprint server for biology · 2026Article
- Breast cancer genomic subtype-specific copy number alterations in metastases.Scientific reports · 2026Article
- An engineered niche delineates metastatic potential of breast cancer.Bioengineering & translational medicine · 2024Article
- The effect of high standard uptake value in lung cancer metastatic lesions on survival.Croatian medical journal · 2023Article
- The Clinical Significance of Genetic Variation in Ovarian Cancer.International journal of molecular sciences · 2023Article
- The genomic regulation of metastatic dormancy.Cancer metastasis reviews · 2023Review
- Tumor heterogeneity and the potential role of liquid biopsy in bladder cancer.Cancer communications (London, England) · 2021Review
- Opportunities and Challenges for Analyzing Cancer Data at the Inter- and Intra-Institutional Levels.JCO precision oncology · 2020Article
- How Cancer Exploits Ribosomal RNA Biogenesis: A Journey beyond the Boundaries of rRNA Transcription.Cells · 2019Review
- A Robust Approach for Identification of Cancer Biomarkers and Candidate Drugs.Medicina (Kaunas, Lithuania) · 2019Article
- Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib.Sarcoma · 2019Article
- Integrated landscape of copy number variation and RNA expression associated with nodal metastasis in invasive ductal breast carcinoma.Oncotarget · 2018Article
- Tumor suppressor PNRC1 blocks rRNA maturation by recruiting the decapping complex to the nucleolus.The EMBO journal · 2018Article
- Evolution of early phase clinical trials in oncology.Journal of molecular medicine (Berlin, Germany) · 2018Review
- P-cadherin: a useful biomarker for axillary-based breast cancer decisions in the clinical practice.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017Article
- Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Article
- The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy.Frontiers in immunology · 2017Article
- Bone: A Fertile Soil for Cancer Metastasis.Current drug targets · 2017Review
- Discordant Mutations in Paired Primary and Metastatic Endometrial Adenocarcinomas Identified by Semiconductor-Based Sequencing for Rapid Cancer Genotyping.Reproductive sciences (Thousand Oaks, Calif.) · 2016Article
- Signatures of post-zygotic structural genetic aberrations in the cells of histologically normal breast tissue that can predispose to sporadic breast cancer.Genome research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 4 countries.
Funding
Abstract
Breast cancer is a major cause of morbidity and mortality in women and its metastatic spread is the principal reason behind the fatal outcome. Metastasis-related research of breast cancer is however underdeveloped when compared with the abundant literature on primary tumors. We applied an unexplored approach comparing at high resolution the genomic profiles of primary tumors and synchronous axillary lymph node metastases from 13 patients with breast cancer. Overall, primary tumors displayed 20% higher number of aberrations than metastases. In all but two patients, we detected in total 157 statistically significant differences between primary lesions and matched metastases. We further observed differences that can be linked to metastatic disease and there was also an overlapping pattern of changes between different patients. Many of the differences described here have been previously linked to poor patient survival, suggesting that this is a viable approach toward finding biomarkers for disease progression and definition of new targets useful for development of anticancer drugs. Frequent genetic differences between primary tumors and metastases in breast cancer also question, at least to some extent, the role of primary tumors as a surrogate subject of study for the systemic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.